AI is increasingly being used across precision oncology to accelerate drug discovery, predict resistance, and guide the design of nanoparticle-based drug-delivery systems. The review highlights AI-guided nanocarriers, adaptive treatment strategies, and multi-omics analysis while emphasizing challenges involving data quality, transparency, generalizability, and regulation.
